Gadobutrol Enhanced MRA of the Supra-aortic Vessels
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 479 participants.
Also called NCT01344447
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose diagnostic
- Phase
- Phase 3
- Enrolled
- 479 participants
- Sponsor
- Registry
-
NCT01344447 -
2010-023001-36
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Austria, China, Czechia, France, Germany, Italy, Poland, South Korea, Sweden, Switzerland, Türkiye
- Registry status
- Completed
Technical summary
Registry record NCT01344447. Allocation not applicable; no masking; primary purpose diagnostic. Start 2011-05-12 (actual); primary completion 2014-05-28 (actual). Results posted on 2015-08-26.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Gadobutrol Enhanced MRA of the Supra-aortic Vessels
- Acronym
- GEMSAV
- Condition
- Carotid Stenosis
- Intervention (Drug)
- Gadobutrol (Gadovist, BAY86-4875)
- Lead sponsor
- Bayer
Record details
- Record id
cardio:ct-nct01344447- Content hash
aab93a5679c2f11f6e43a002d81fc599c5192795b0e53727d014ea6b03467fb7